Clinical Trial Update: Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites [Phase 1]

View source ↗

Summary

This update reports the completion of a Phase 1 trial evaluating the safety, immunogenicity, and protective efficacy of three or five administrations of GAP3KO …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• GAP3KO sporozoites (GAP3KO attenuated Plasmodium falciparum sporozoites)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Plasmodium Falciparum Infection | Phase 1 | Status: COMPLETED